The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing
about
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerThe KRAS-variant is associated with risk of developing double primary breast and ovarian cancerNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.SNPs in microRNA binding sites as prognostic and predictive cancer biomarkersAssociation study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).MicroRNA binding site polymorphisms as biomarkers in cancer management and research.The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximabMicroRNA-mediated regulation of KRAS in cancerMicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium.The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPDRole of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing"Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.KRAS polymorphisms are associated with survival of CRC in Chinese population.KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.
P2860
Q27851690-7C198ADA-931E-42D6-A87F-305FBCBD1210Q28729202-2CC87A7B-6C38-4686-B407-7DC7C565FDD6Q30374367-8C54C349-EB64-4B4C-AFFF-4EACDC791263Q33640984-113E2E45-062A-40B4-8F08-D73E9A01818FQ33855053-675AD520-F5F8-4A3A-9F16-CFA11E96770EQ34019040-455A280F-767F-41E8-AD30-8ED25CEE0E9CQ34134870-8C47D79A-9046-43AD-934A-4E7D0FDBDD35Q34138308-CC5CC332-D7AA-4A3E-96A8-94CA8260A667Q34205192-30E47662-37DF-4D01-A1A7-1AEE5818E5FAQ34483581-1ED7FE7F-7466-42BC-83CF-BE595426411BQ34678120-C5CA5A49-97C7-49EA-BB55-78D3D99D79E0Q35156802-A95CB078-DCE0-4AC0-B785-75D1DD6461ABQ35795350-14036193-3E66-41C8-9528-7F0E7FC1D65EQ35853140-35AA3D9F-BE7A-4881-8258-96425AF538F1Q35981873-91D80CD5-A525-4C33-88A3-5E5CBBBF38B6Q36287562-F7C7648A-4DE2-4BC8-AA83-F8D6184D3309Q37393598-353B0BB5-9085-4EBB-8EFA-3F98320184F1Q37420213-8CB32B59-99EC-4988-A57B-D48EB4602212Q39053707-6083BCBD-A833-4FC1-909E-48CA42572499Q41170152-E0B83F51-9CFD-4282-B80A-8E94F1878BAAQ41949668-87C726A0-1DCF-417D-9852-28E9555E9083Q43496062-0F71ED20-42C6-4A07-A169-D28703C0C959Q47652779-90BF6EC6-34F2-44F6-AF95-D3A4990D8867Q47704968-BDD55D9E-EC6E-4FA7-B8E5-B8C6179A948D
P2860
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The role of KRAS rs61764370 in ...... lications for clinical testing
@ast
The role of KRAS rs61764370 in ...... lications for clinical testing
@en
type
label
The role of KRAS rs61764370 in ...... lications for clinical testing
@ast
The role of KRAS rs61764370 in ...... lications for clinical testing
@en
prefLabel
The role of KRAS rs61764370 in ...... lications for clinical testing
@ast
The role of KRAS rs61764370 in ...... lications for clinical testing
@en
P2093
P2860
P50
P1476
The role of KRAS rs61764370 in ...... lications for clinical testing
@en
P2093
Allison F Vitonis
Andrew Berchuck
Andrew K Godwin
Anna de Fazio
Anne M van Altena
Arto Leminen
BCFR Investigators
Beth Y Karlan
P2860
P304
P356
10.1158/1078-0432.CCR-10-3405
P407
P50
P577
2011-03-08T00:00:00Z